Interest of TTC for the Early Diagnosis of Acute Myocardial Infarction at Autopsy

NCT04924426 | Unknown

• 1 other identifier: RECHMPL21_0283
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Ischemic heart disease is the leading cause of death worldwide and the leading cause of sudden cardiac death. However, its post-mortem diagnosis is particularly difficult because the gross examination of the heart is usually normal at the autopsy . The diagnosis is therefore often based on a set of indirect arguments, such as the patient's medical and clinical history and the degree of occlusion of the coronary arteries. The formal diagnosis of acute myocardial infarction (AMI) currently relies on standard histological examination. However, histological findings often require a prolonged survival time of several hours to be highlighted. Triphenyltetrazolium chloride (TTC) is a salt that reacts with lactate dehydrogenases contained in still viable myocardial cells, forming a red pigment visible to the naked eye, (1,3,5 triphenylformazan). Ischemia-induced cell death, which occurs within minutes of the causative event, is responsible for the leakage of lactate deshydrogenase into the extracellular medium and thus results in the absence of formazan formation in the infarcted area, which displays an easily identifiable pale unstained color. It has been suggested that the use of TTC would allow the identification of MI as early as one hour of survival in animal models, before the usual macroscopic and microscopic signs are visible. It could therefore represent an attractive forensic tool for the early diagnosis of AMI at the autopsy.

Conditions

Myocardial Infarction

Keywords

Early Acute Myocardial Infarction; TTC; Sudden death; Early markers; biochemicla markers

Outcome Measures

Primary Outcomes (1)

• Negative colorimetric reaction to TTC of infarcted myocardial tissue

  Negative colorimetric reaction to TTC of infarcted myocardial tissue

  day 1

Secondary Outcomes (2)

• Survival time (time from initial symptoms to death)

  day 1

• Post-mortem interval (time from death to autopsy)

  day 1

Study Arms (2)

Patients with AMI

Patients with AMI

Procedure: TTC immersion

Patients with no AMI

Patients with no AMI

Procedure: TTC immersion

Interventions

TTC immersion PROCEDURE

TTC immersion

Patients with AMI; Patients with no AMI

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Suspicion of death due to acute myocardial infarction

You may qualify if:

• Adult patients autopsied at the Forensic Institute of the CHU of MONTPELLIER whose ante-mortem (medical history, cardiovascular risk factors, clinical history) and autopsy data (significant coronary stenosis associated or not with an endoluminal thrombus, scars of old infarction, absence of other identified cause of death) suggest AMI as the cause of death.
• Known survival time and postmortem interval.

You may not qualify if:

• \- Putrefied bodies

Sponsors & Collaborators

• University Hospital, Montpellier: lead

Study Sites (1)

Uhmontpellier

Montpellier, 34295, France

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

myocardial fragments

MeSH Terms

Conditions

Myocardial Infarction; Death, Sudden

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis; Death

Study Officials

• Pierre-Antoine Peyron, PH

  University Hospital, Montpellier

  STUDY DIRECTOR

Central Study Contacts

Manon Blanc, resident

CONTACT

06-15-63-14-58; ma-blanc@chu-montpellier.fr

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 10, 2021
• First Posted: June 14, 2021
• Study Start: May 1, 2021
• Primary Completion: August 1, 2022
• Study Completion: August 30, 2022
• Last Updated: June 14, 2021

Record last verified: 2021-06

Locations

FR (1)